Physician profile
Jeffrey Freeman
NPI 1831127091
$218,917.89
in general payments reported to CMS, 2019-2025
72 companies · $11K in 2025
The $11K reported for 2025 was more than what 90% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $89K · 2020: $29K · 2021: $20K · 2022: $37K · 2023: $24K · 2024: $9,861 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $9,910 · Education: $154.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,015.00 |
| Food and Beverage | $9,909.81 |
| Education | $153.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $114,549.37 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Amarin Pharma, INC. | $43,750.79 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $21,607.40 | 2021-2025 | |
| Amgen INC. | $12,299.66 | 2019-2025 | Repatha, Tepezza, Repatha |
| Mannkind Corporation | $4,504.24 | 2019-2025 | Afrezza |
| Valeritas, INC. | $4,476.41 | 2019 | |
| Sanofi-Aventis U.S. LLC | $3,843.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $2,728.25 | 2019-2025 | Jardiance, Synjardy |
| Lilly USA, LLC | $2,043.78 | 2019-2025 | Mounjaro, Jardiance, Lyumjev |
| Medtronic, INC. | $985.45 | 2021-2025 | Minimed 780g, Minimed 770g, Inpen Smart Insulin Delivery System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $822.04 | 2019-2023 | Cycloset |
| Merck Sharp & Dohme LLC | $497.23 | 2019-2023 | |
| Abbott Laboratories | $436.12 | 2020-2025 | Freestyle Libre 3 |
| Corcept Therapeutics | $413.96 | 2019-2025 | Korlym |
| Xeris Pharmaceuticals, INC. | $374.43 | 2020-2024 | Gvoke Hypopen, Recorlev |
Show all 72 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $357.86 | 2022-2025 | |
| Abbvie INC. | $338.03 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $257.93 | 2019-2025 | Farxiga |
| Dexcom, INC. | $251.36 | 2019-2024 | Dexcom G6 Transmitter |
| Esperion Therapeutics, INC. | $231.56 | 2020-2025 | Nexletol |
| Becton, Dickinson and Company | $197.82 | 2019-2022 | |
| Zealand Pharma US, INC. | $195.78 | 2020-2022 | |
| Cequr Corporation | $165.01 | 2022-2024 | Cequr Simplicity |
| Takeda Pharmaceuticals U.S.A., INC. | $159.91 | 2020-2022 | |
| Horizon Therapeutics Plc | $159.55 | 2019-2023 | Tepezza |
| Recordati_rare_diseases_inc. | $155.59 | 2023-2025 | Isturisa, Signifor Lar |
| Intra-Sana Laboratories | $154.19 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Tandem Diabetes Care, INC. | $143.81 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Astellas Pharma US INC | $133.18 | 2024-2025 | Veozah |
| Opko Pharmaceuticals, LLC | $132.66 | 2019-2024 | Rayaldee |
| Alexion Pharmaceuticals, INC. | $127.69 | 2021-2024 | Strensiq |
| Shire North American Group INC | $118.52 | 2019 | |
| Radius Health, INC. | $117.53 | 2020-2025 | Tymlos |
| Amneal Pharmaceuticals LLC | $108.30 | 2021-2022 | |
| Kyowa Kirin, INC. | $107.80 | 2022-2025 | Crysvita |
| Amphastar Pharmaceuticals, INC. | $107.37 | 2023-2025 | Baqsimi |
| Regeneron Pharmaceuticals, INC. | $107.29 | 2019 | |
| Bigfoot Biomedical INC | $106.05 | 2021 | |
| Agepha Pharma Fz LLC | $104.33 | 2024-2025 | Lodoco |
| Intuity Medical INC | $100.92 | 2023 | Pogo Automatic Blood Glucose Monitoring System |
| Chiesi USA, INC. | $98.25 | 2024-2025 | Mycapssa, Myalept, Juxtapid |
| Ascendis Pharma Endocrinology INC | $89.91 | 2023-2025 | Yorvipath |
| Ipsen Biopharmaceuticals, INC | $87.51 | 2019-2023 | Somatuline Depot |
| Medtronic Minimed, INC. | $86.38 | 2019-2020 | |
| Ultragenyx Pharmaceutical INC. | $81.25 | 2020-2022 | |
| Ascensia Diabetes Care US INC. | $76.25 | 2022-2024 | |
| Insulet Corporation | $74.97 | 2021-2025 | Omnipod |
| Pfizer INC. | $73.48 | 2020-2024 | |
| Ibsa Pharma INC. | $67.00 | 2020-2024 | Licart, Tirosint |
| Sequel Med Tech, LLC | $62.99 | 2025 | Twiist |
| Regeneron Healthcare Solutions, INC. | $60.43 | 2019 | |
| Madrigal Pharmaceuticals | $52.90 | 2025 | Rezdiffra |
| Lifescan, INC. | $50.15 | 2019-2020 | |
| Eisai INC. | $47.27 | 2019 | |
| Averitas Pharma INC. | $47.05 | 2024-2025 | Qutenza |
| Currax Pharmaceuticals LLC | $46.19 | 2021-2023 | Contrave |
| Sun Pharmaceutical Industries INC. | $39.60 | 2020 | |
| Clarus Therapeutics INC. | $35.25 | 2021 | |
| Neurocrine Biosciences, INC. | $29.77 | 2025 | |
| Acerus Pharmaceuticals Corporation | $27.76 | 2020 | |
| Mallinckrodt Hospital Products INC. | $27.46 | 2020 | |
| Janssen Pharmaceuticals, INC | $26.93 | 2019 | |
| Ionis Pharmaceuticals, INC. | $20.78 | 2025 | Tryngolza |
| Beta Bionics, INC. | $19.09 | 2023-2024 | Ilet Bionic Pancreas |
| Janssen Biotech, INC. | $18.12 | 2021 | |
| Amryt Pharma Holdings LTD | $17.45 | 2022 | |
| Ucb, INC. | $15.21 | 2021 | |
| Tolmar, INC. | $14.03 | 2023 | |
| Almatica Pharma LLC | $13.80 | 2025 | Teriparatide |
| Hikma Pharmaceuticals USA | $13.22 | 2021 | |
| Travere Therapeutics, INC. | $12.58 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Freeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.